*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2023 | The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies Expert opinion on drug discovery · preclinical | PMID 37042028 |
| 2022 | Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound Biomolecules · preclinical | PMID 36291618 |
| 2020 | Prenatal to early postnatal neurotrophic treatment prevents Alzheimer-like behavior and pathology in mice Alzheimer's research & therapy · preclinical | PMID 32854771 |
| 2017 | Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound Alzheimer's research & therapy · preclinical | PMID 28655344 |
| 2016 | Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease Molecular neurodegeneration · preclinical | PMID 27400746 |
| 2015 | Elevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound Journal of Alzheimer's disease : JAD · preclinical | PMID 26401692 |
| 2014 | Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease Neurobiology of disease · preclinical | PMID 25046994 |
| 2014 | Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound Neurobiology of aging · preclinical | PMID 24702821 |
P21 (P21 (Cintirorgon-class; ciliary-neurotrophic-factor-mimetic peptide)). Synthetic peptidomimetic designed to mimic ciliary neurotrophic factor (CNTF) activity, reported preclinically to promote neurogenesis and reduce tau hyperphosphorylation.
Commonly discussed uses: neurogenesis / neurodegeneration research (preclinical). The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Note: most uses are not approved indications.
Mechanism: Synthetic peptidomimetic designed to mimic ciliary neurotrophic factor (CNTF) activity, reported preclinically to promote neurogenesis and reduce tau hyperphosphorylation.
Reported considerations: no human safety data. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Preclinical research peptide. No human data. Not approved. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low research-defined, typical no established human dose, high unknown. Administration: subcutaneous (research), intranasal (research). Half-life: not characterised in humans.
Australian status: Not ARTG-registered; research. Preclinical research peptide. No human data. Not approved. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: research-defined; storage: frozen aliquots.
Commonly discussed combinations (anecdotal for unapproved compounds): research peptide; no protocols. Stacking increases interaction/safety uncertainty.